Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discordance of the Repeat GeneXpert MTB/RIF Test for Rifampicin Resistance Detection Among Patients Initiating MDR-TB Treatment in Uganda.
Ssengooba W, de Dieu Iragena J, Komakech K, Okello I, Nalunjogi J, Katagira W, Kimuli I, Adakun S, Joloba ML, Torrea G, Kirenga BJ. Ssengooba W, et al. Among authors: adakun s. Open Forum Infect Dis. 2021 Apr 2;8(6):ofab173. doi: 10.1093/ofid/ofab173. eCollection 2021 Jun. Open Forum Infect Dis. 2021. PMID: 34189166 Free PMC article.
Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda.
Ssengooba W, Komakech K, Namiiro S, Byabajungu H, Nalunjogi J, Katagira W, Kimuli I, Joloba ML, Adakun S, Nakiyingi L, Torrea G, Kirenga BJ. Ssengooba W, et al. Among authors: adakun s. J Clin Tuberc Other Mycobact Dis. 2021 Nov 6;25:100286. doi: 10.1016/j.jctube.2021.100286. eCollection 2021 Dec. J Clin Tuberc Other Mycobact Dis. 2021. PMID: 34816021 Free PMC article.
Prevalence of COVID-19 infection in TB clinics in Kampala, Uganda.
Otaalo B, Cevik M, Mwebesa E, Nabisere-Arinaitwe R, Zawedde-Muyanja S, Nampala J, Nanziri C, Alinaitwe L, Aber F, Bayigga J, Nankinga B, Laker E, Owarwo NC, Sabiiti W, Adakun S, Kirenga B, Turyahabwe S, Sloan DJ, Sekaggya-Wiltshire C. Otaalo B, et al. Among authors: adakun s. Int J Tuberc Lung Dis. 2023 Jun 1;27(6):481-483. doi: 10.5588/ijtld.23.0010. Int J Tuberc Lung Dis. 2023. PMID: 37231596 No abstract available.
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial.
Goodall RL, Nunn AJ, Meredith SK, Bayissa A, Bhatnagar AK, Chiang CY, Conradie F, Gopalan N, Gurumurthy M, Kirenga B, Kiria N, Meressa D, Moodliar R, Ngubane N, Rassool M, Sanders K, Solanki R, Squire SB, Teferi M, Torrea G, Tsogt B, Tudor E, Van Deun A, Rusen ID; STREAM study collaborators. Goodall RL, et al. Lancet Respir Med. 2024 Dec;12(12):975-987. doi: 10.1016/S2213-2600(24)00186-3. Epub 2024 Oct 1. Lancet Respir Med. 2024. PMID: 39366400 Free article. Clinical Trial.
Disability, comorbidities and risk determinants at end of TB treatment in Kenya, Uganda, Zambia and Zimbabwe.
Kenya, Uganda, Zambia, and Zimbabwe TB Disability Study Group (members listed here in alphabetical order):; Adakun SA, Banda FM, Bloom A, Bochnowicz M, Chakaya J, Chansa A, Chiguvare H, Chimzizi R, Colvin C, Dongo JP, Durena A, Duri C, Edmund R, Harries AD, Kathure I, Kavenga FN, Lin Y, Luzze H, Mbithi I, Mputu M, Mubanga A, Nair D, Ngwenya M, Okotu B, Owiti P, Owuor A, Thekkur P, Timire C, Turyahabwe S, Tweyongyere E, YaDiul M, Zachariah R, Zimba K. Kenya, Uganda, Zambia, and Zimbabwe TB Disability Study Group (members listed here in alphabetical order):, et al. Among authors: adakun sa. IJTLD Open. 2024 May 1;1(5):197-205. doi: 10.5588/ijtldopen.24.0082. eCollection 2024 May. IJTLD Open. 2024. PMID: 39022778 Free PMC article.
13 results